Tags

Type your tag names separated by a space and hit enter

Effects of adding prescription omega-3 acid ethyl esters to simvastatin (20 mg/day) on lipids and lipoprotein particles in men and women with mixed dyslipidemia.
Am J Cardiol. 2008 Aug 15; 102(4):429-33.AJ

Abstract

Prescription omega-3 acid ethyl esters (P-OM3) are commonly used for treatment of very high triglyceride levels, often in combination with a statin, to lower persistent hypertriglyceridemia. This randomized, crossover trial evaluated 6 weeks of combination therapy with simvastatin 20 mg/day plus P-OM3 4 g/day or placebo in 39 men and women (average age 58 years) with a triglyceride concentration 200 to 600 mg/dl and non-high-density lipoprotein (non-HDL) cholesterol greater than their National Cholesterol Education Program treatment goals after a 5-week diet lead-in. Non-HDL cholesterol decreased from baseline (209 mg/dl) by 40% for P-OM3 + simvastatin compared with 34% for placebo + simvastatin (p <0.001). Favorable changes for P-OM3 + simvastatin versus placebo + simvastatin were also observed for very low-density lipoprotein (VLDL) cholesterol (-42% vs -22%), triglyceride (-44% vs -29%), total cholesterol (-31% vs -26%), HDL cholesterol (+16% vs +11%), apolipoprotein B (-32% vs -28%), total cholesterol:HDL cholesterol ratio (-39% vs -33%), triglyceride:HDL cholesterol ratio (-51% vs -37%), and systolic (-5.0 vs 0.3 mm Hg) and diastolic (-3.3 vs -1.8 mm Hg) blood pressures (p <0.05 for all). VLDL particle concentration and size decreased and LDL particle size increased significantly more with P-OM3 + simvastatin than with placebo + simvastatin (all p <0.05). Changes in LDL cholesterol, LDL particle concentration, HDL particle size and concentration, and apolipoprotein A-I did not differ significantly between treatments. In conclusion, P-OM3 + simvastatin appears to be a useful therapeutic option for the management of mixed dyslipidemia.

Authors+Show Affiliations

Provident Clinical Research, Glen Ellyn, Illinois, USA. KMAKI@ProvidentCRC.comNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

18678300

Citation

Maki, Kevin C., et al. "Effects of Adding Prescription Omega-3 Acid Ethyl Esters to Simvastatin (20 Mg/day) On Lipids and Lipoprotein Particles in Men and Women With Mixed Dyslipidemia." The American Journal of Cardiology, vol. 102, no. 4, 2008, pp. 429-33.
Maki KC, McKenney JM, Reeves MS, et al. Effects of adding prescription omega-3 acid ethyl esters to simvastatin (20 mg/day) on lipids and lipoprotein particles in men and women with mixed dyslipidemia. Am J Cardiol. 2008;102(4):429-33.
Maki, K. C., McKenney, J. M., Reeves, M. S., Lubin, B. C., & Dicklin, M. R. (2008). Effects of adding prescription omega-3 acid ethyl esters to simvastatin (20 mg/day) on lipids and lipoprotein particles in men and women with mixed dyslipidemia. The American Journal of Cardiology, 102(4), 429-33. https://doi.org/10.1016/j.amjcard.2008.03.078
Maki KC, et al. Effects of Adding Prescription Omega-3 Acid Ethyl Esters to Simvastatin (20 Mg/day) On Lipids and Lipoprotein Particles in Men and Women With Mixed Dyslipidemia. Am J Cardiol. 2008 Aug 15;102(4):429-33. PubMed PMID: 18678300.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Effects of adding prescription omega-3 acid ethyl esters to simvastatin (20 mg/day) on lipids and lipoprotein particles in men and women with mixed dyslipidemia. AU - Maki,Kevin C, AU - McKenney,James M, AU - Reeves,Matthew S, AU - Lubin,Barry C, AU - Dicklin,Mary R, Y1 - 2008/05/22/ PY - 2008/01/04/received PY - 2008/03/29/revised PY - 2008/03/29/accepted PY - 2008/8/6/pubmed PY - 2008/9/20/medline PY - 2008/8/6/entrez SP - 429 EP - 33 JF - The American journal of cardiology JO - Am J Cardiol VL - 102 IS - 4 N2 - Prescription omega-3 acid ethyl esters (P-OM3) are commonly used for treatment of very high triglyceride levels, often in combination with a statin, to lower persistent hypertriglyceridemia. This randomized, crossover trial evaluated 6 weeks of combination therapy with simvastatin 20 mg/day plus P-OM3 4 g/day or placebo in 39 men and women (average age 58 years) with a triglyceride concentration 200 to 600 mg/dl and non-high-density lipoprotein (non-HDL) cholesterol greater than their National Cholesterol Education Program treatment goals after a 5-week diet lead-in. Non-HDL cholesterol decreased from baseline (209 mg/dl) by 40% for P-OM3 + simvastatin compared with 34% for placebo + simvastatin (p <0.001). Favorable changes for P-OM3 + simvastatin versus placebo + simvastatin were also observed for very low-density lipoprotein (VLDL) cholesterol (-42% vs -22%), triglyceride (-44% vs -29%), total cholesterol (-31% vs -26%), HDL cholesterol (+16% vs +11%), apolipoprotein B (-32% vs -28%), total cholesterol:HDL cholesterol ratio (-39% vs -33%), triglyceride:HDL cholesterol ratio (-51% vs -37%), and systolic (-5.0 vs 0.3 mm Hg) and diastolic (-3.3 vs -1.8 mm Hg) blood pressures (p <0.05 for all). VLDL particle concentration and size decreased and LDL particle size increased significantly more with P-OM3 + simvastatin than with placebo + simvastatin (all p <0.05). Changes in LDL cholesterol, LDL particle concentration, HDL particle size and concentration, and apolipoprotein A-I did not differ significantly between treatments. In conclusion, P-OM3 + simvastatin appears to be a useful therapeutic option for the management of mixed dyslipidemia. SN - 0002-9149 UR - https://www.unboundmedicine.com/medline/citation/18678300/Effects_of_adding_prescription_omega_3_acid_ethyl_esters_to_simvastatin__20_mg/day__on_lipids_and_lipoprotein_particles_in_men_and_women_with_mixed_dyslipidemia_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0002-9149(08)00655-3 DB - PRIME DP - Unbound Medicine ER -